Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 20 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 7 pages · English

Summary by 6ix AI

This authorization marks NULIBRY as the first approved therapy for this ultra-rare genetic disorder in Europe. The press release highlights the significance of this treatment for patients with a median survival age of about four years. The approval is based on clinical trial data demonstrating the efficacy and safety of NULIBRY compared to historical controls. Zydus Lifesciences expresses its commitment to addressing rare diseases through this milestone achievement.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases